Fentanyl Transdermal Patch and Mavorixafor: Interaction Details
- Mavorixafor
- Xolremdi
- Fentanyl Transdermal Patch
- DuragesicAbstralSubsys +3 more
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Fentanyl Transdermal Patch and Mavorixafor interaction:
Mavorixafor
- Xolremdi
We don't have a drug information page for Mavorixafor yet. Have a question about Mavorixafor? Ask a pharmacist, free →
Fentanyl Transdermal Patch
- Duragesic
- Abstral
- Subsys
- Ionsys
- Actiq
- Fentora
What Happens When You Take Fentanyl Transdermal Patch With Mavorixafor
What can happen when they are taken together (rated Major)
Increased with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When mavorixafor, a CYP3A4 , is given together with a CYP3A4 substrate that has a (NTI), exposure to that substrate may rise, which may raise the likelihood of adverse events linked to it. For CYP3A4 substrates in which even small shifts in concentration can cause serious adverse reactions, adverse reactions should be monitored more often during with mavorixafor. A drug interaction study in healthy subjects found that giving mavorixafor 400 mg with midazolam (a CYP3A4 substrate) raised midazolam by 1.1-fold and by 1.7-fold, respectively.1
The Fentanyl Transdermal Patch and Mavorixafor Interaction, Explained
Mavorixafor (Xolremdi) can slow down , a liver enzyme that helps your body break down fentanyl. With less breakdown, more fentanyl can stay in your body. That could mean stronger effects and more side effects from the patch, like extra sleepiness, slowed breathing, dizziness, or nausea.
In a study with a different drug that uses the same enzyme (midazolam), mavorixafor raised drug exposure by about 1.7-fold. Fentanyl is a drug where small changes can matter. Please keep using both as prescribed, and talk with your pharmacist or doctor. Your care team can adjust and individualize your dose and may monitor you more closely.
Mechanism: Mavorixafor inhibits , the primary pathway for fentanyl . Fentanyl is active itself (not a ), so is expected to increase fentanyl exposure and -related toxicity.
- Magnitude: Not studied with fentanyl. With midazolam, mavorixafor 400 mg raised 1.1-fold and 1.7-fold.
- Onset: Unspecified. Evidence: probable. Severity: major.
- Risk: and , as small concentration changes can be clinically significant.
- Management: Monitor more frequently for CYP3A4 -related adverse reactions. Individualize the fentanyl dose as needed.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Fentanyl Transdermal Patch and Mavorixafor Interact
The likely mechanism
of -mediated by mavorixafor
How to Manage the Fentanyl Transdermal Patch and Mavorixafor Interaction
The documented advice is closer monitoring when mavorixafor is used with drugs like fentanyl, where small increases in levels can cause serious effects.
- Keep using both medicines exactly as prescribed.
- Your care team may monitor you more often and may adjust and individualize your fentanyl dose.
- Tell your pharmacist or prescriber about any new sleepiness, confusion, slow or shallow breathing, or unusual dizziness.
- Do not change or stop either medicine on your own.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Fentanyl Transdermal Patch or Mavorixafor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: XOLREMDI oral capsules, mavorixafor oral capsules
In a drug interaction study conducted in healthy subjects, giving mavorixafor (a ) 400 mg together with midazolam (a CYP3A4 ) raised midazolam by 1.1-fold and by 1.7-fold, respectively.1
Fentanyl Transdermal Patch and Mavorixafor: Common Questions
How serious is the Fentanyl Transdermal Patch and Mavorixafor interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Fentanyl Transdermal Patch and Mavorixafor interaction managed?
The documented advice is closer monitoring when mavorixafor is used with drugs like fentanyl, where small increases in levels can cause serious effects. Keep using both medicines exactly as prescribed. Your care team may monitor you more often and may adjust and individualize your fentanyl dose. Tell your pharmacist or prescriber about any new sleepiness, confusion, slow or shallow breathing, or u… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Fentanyl Transdermal Patch and Mavorixafor Interaction
Ask in your own words about taking Fentanyl Transdermal Patch and Mavorixafor together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: XOLREMDI(TM) oral capsules, mavorixafor oral capsules. X4 Pharmaceuticals, Inc. (Per FDA), Boston, MA, 2024. DailyMed
Other Serious Interactions of Fentanyl Transdermal Patch and Mavorixafor
Also serious with Mavorixafor
- Acetaminophen and CodeineContraindicated
- AmitriptylineContraindicated
- Aripiprazole InjectionContraindicated
- BrexpiprazoleContraindicated
Also serious with Fentanyl Transdermal Patch
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.